Katherine Nevin

Employment

• GlaxoSmithKline Research and Development
  2012 - Present

Education

• Barts and The London School of Medicine and Dentistry PhD
  2008 - 2011

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.
  British journal of clinical pharmacology 2018 DOI: 10.1111/bcp.13669
  +Save
• Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
  British journal of haematology 2016 DOI: 10.1111/bjh.14145
  +Save
• Constitutive Autophagy and Nucleophagy during Epidermal Differentiation.
  The Journal of investigative dermatology 2016 DOI: 10.1016/j.jid.2016.03.016
  +Save
• Quantitation OF ARGS aggrecan fragments in synovial fluid, serum and urine from osteoarthritis patients.
  Osteoarthritis and cartilage 2014 DOI: 10.1016/j.joca.2014.02.930
  +Save
• The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling.
  Oncogene 2012 DOI: 10.1038/onc.2012.338
  +Save
• TALE homeodomain proteins regulate site-specific terminal differentiation, LCE genes and epidermal barrier.
  Journal of cell science 2011 DOI: 10.1242/jcs.077552
  +Save
• TPL-2-mediated activation of MAPK downstream of TLR4 signaling is coupled to arginine availability.
  Science signaling 2010 DOI: 10.1126/scisignal.2000934
  +Save
• PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.
  Molecular cell 2010 DOI: 10.1016/j.molcel.2010.01.031
  +Save
• Akt-dependent Pp2a activity is required for epidermal barrier formation during late embryonic development.
  Development (Cambridge, England) 2009 DOI: 10.1242/dev.037010
  +Save